Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Ferrata Storti Foundation
2016-08-01
|
Series: | Haematologica |
Online Access: | https://haematologica.org/article/view/7804 |